🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 2 mab completed

    1 trial

  2. Inactivated types 1, 2, and 3 poliovirus, D antigens

    Sanofi Pasteur

    Poliomyelitis

    phase 2 mab completed

    1 trial

  3. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  4. Infigratinib

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial

  5. Infigratinib

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

  6. Infigratinib 0.016 mg/kg

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule completed

    1 trial

  7. Infigratinib is provided as a single dose of minitablets for oral administration

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial

  8. Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, AZD0171, Oleclumab, Mycophenolate Mofetil 250 mg Capsules, Inflectra 100 mg powder for concentrate for solution for infusion, CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., volrustomig, CISPLATIN , Monalizumab, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, Rilvegostomig, Inflectra 100 mg powder for concentra

    AstraZeneca AB

    Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, REGN7508

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 2 small molecule active

    1 trial

  10. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  11. Injection of IAH0968+Gemcitabine+Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HER2 Gene Mutation

    phase 2 other active

    1 trial

  12. Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

    The George Institute

    Ovarian Cancer

    phase 2 other active

    1 trial

  13. Intismeran autogene

    Merck KGaA, Darmstadt, Germany

    Malignant Melanoma

    phase 2 mab active

    1 trial

  14. Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis of HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Intravenous Gemini

    REVELATION BIOSCIENCES, INC.

    Renal Insufficiency, Chronic

    phase 2 small molecule completed

    1 trial

  16. Intraventricular Pemetrexed

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leptomeningeal Metastasis

    phase 2 small molecule active

    1 trial

  17. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Serous Chorioretinopathy

    phase 2 small molecule completed

    1 trial

  18. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  19. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Age-Related Macular Degeneration

    phase 2 small molecule completed

    2 trials

  20. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Retinal Vein Occlusion

    phase 2 small molecule completed

    1 trial

  21. Intravitreal injection of KH902

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neovascular Age-related Macular Degeneration

    phase 2 mab completed

    1 trial

  22. Iparomlimab and Tuvonralimab Injection in combination with TFOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. Iparomlimab and Tuvonralimab combined with lenvatinib and SOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  24. Ipilimumab

    United Therapeutics Europe Ltd

    BCLC Stage B Hepatocellular Carcinoma

    phase 2 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources